FDA Clears Qiagen KRAS Test as CDx for Erbitux
July 09, 2012
FDA Clears Qiagen KRAS Test as CDx for Erbitux
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Dx Focus: Clarient to Offer Qiagen Therascreen KRAS Test as Erbitux CDx
January 31, 2013 / PCR Insider - Qiagen Enters Companion Dx Market with Approval of KRAS Test Kit for Erbitux; LDT Impact Unknown
July 11, 2012 / Pharmacogenomics Reporter - Qiagen, Eli Lilly Enter CDx Deal
February 14, 2013 / GenomeWeb Daily News - Qiagen's Experience Developing KRAS CDx for Erbitux Yields Lessons for Rx/Dx Development
November 28, 2012 / Pharmacogenomics Reporter - FDA Clears Qiagen's Rotor-Gene Q MDx Platform, Influenza A/B Assay
April 17, 2012 / GenomeWeb Daily News